预约演示
更新于：2025-05-23
Eprosartan Mesylate
依普沙坦
更新于：2025-05-23
概要
基本信息
药物类型 小分子化药 |
别名 (E)-2-butyl-1-(p-carboxybenzyl)-α-2-thenylimidazole-5-acrylic acid、(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid、(E)-α{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid + [18] |
靶点 |
作用方式 拮抗剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-12-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28N2O7S2 |
InChIKeyDJSLTDBPKHORNY-XMMWENQYSA-N |
CAS号144143-96-4 |
关联
8
项与 依普沙坦 相关的临床试验NCT04606563
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?
NCT01631227
A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension
NCT01502904
Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents
100 项与 依普沙坦 相关的临床结果
登录后查看更多信息
100 项与 依普沙坦 相关的转化医学
登录后查看更多信息
100 项与 依普沙坦 相关的专利（医药）
登录后查看更多信息
850
项与 依普沙坦 相关的文献（医药）2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Water Resources and Industry
Monitoring pharmaceuticals and personal care products to assess water quality changes and pollution sources in a drinking water reservoir catchment
作者: Witkowski, Andrzej J. ; Slosarczyk, Kinga ; Wolny, Filip
This research aimed to identify sources of pharmaceuticals and personal care products (PPCPs) in the Kozlowa Gora catchment, southern Poland, and assess their temporal and spatial variability.PPCP monitoring was conducted from 2020 to 2022.Samples were taken from the Brynica River and other streams.Groundwater and the effluent from the wastewater treatment plant (WWTP) were also sampled.The monitoring screened 109 PPCPs using the LC-MS/MS method.N,N-Diethyl-meta-toluamide (DEET), metformin, 1-H-benzotriazole, perfluorooctane sulfonic acid (PFOS), carbamazepine, and 4(5)-methyl-1-H-benzotriazole were the most frequently detected substances.The highest total PPCP concentrations in surface waters reached 30790 ng/L, with up to 53 compounds detected at one point.Results indicated temporal and spatial variability, with higher concentrations and more PPCPs during winter periods and increased contamination downstream from the WWTP.DEET was the only contaminant consistently found in the shallow aquifer discharged into the Brynica, however groundwater impact on the river ′s water quality is negligible.The study confirmed the WWTP as the primary source of PPCPs, with the number of detected substances in effluent samples amounting to 65 and their total concentrations reaching 148265 ng/L.Addnl. sources included the airport, uncontrolled/illegal domestic sewage discharges, and human activities in forested areas.This study was the first in Poland to implement a PPCP monitoring approach in a drinking water reservoir catchment area using multiple monitoring points and sampling campaigns.The results revealed the constant presence of PPCPs in a moderately urbanised catchment area, highlighting the importance of regular monitoring to understand PPCP migration in the environment.
2025-02-12CURRENT PHARMACEUTICAL DESIGN
Eprosartan Reduces Inflammation and Oxidative Stress in Ethanol-induced Hepatotoxicity
Article
作者: Mansourian, Mahboubeh ; Jahantab, Mohammad Bagher ; Karimi, Farzaneh ; Larki, Rozina Abbasi ; Mirghaed, Ali Taheri ; Azizi, Mahdokht ; Behrouj, Hamid ; Mehrabi, Sadrollah ; Daryabor, Gholamreza ; Abdzadeh, Soroor ; Doustimotlagh, Amir Hossein
Introduction::
Eprosartan is an effective blood pressure medication that blocks the Angiotensin
Type 1 (AT1) receptor. The studies conducted on Eprosartan showed anti-oxidative stress effects and modulating
inflammatory mechanisms. The current research is designed to clarify and examine the possible advantageous
impacts of Eprosartan against chronic ethanol-induced hepatic damage.
Method::
Twenty-four male Sprague-Dawley rats were haphazardly separated into four groups. The control
group received normal saline 1 g/kg for 35 days (group 1). The EtOH group received 7 g/kg of 40% ethanol
orally for 35 days (group 2). The EtOH+ EP group was pretreated with 60 mg/kg of Eprosartan dissolved in
normal saline orally and, after 60 minutes, received 7 g/kg of 40% ethanol orally for 35 days (group 3). The
EP group received only Eprosartan 60 mg/kg dissolved in normal saline for 35 days (group 4). The levels of
biochemical parameters, oxidative stress markers, pro-inflammatory cytokines, and histopathological staining
were evaluated in serum and liver tissue. The interactive behavior of Eprosartan with Tumor Necrosis Factor-α
(TNF-α) protein was also explained by molecular docking.
Results::
Pre-treatment with Eprosartan (60 mg/kg) notably diminished the elevation in serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT) enzymes, total
triglyceride, cholesterol, total bilirubin, and inflammatory cytokines including TNF-α, Interleukin-1β (IL-1β)
and Interleukin-6 (IL-6) levels, which were induced by alcohol administration (P-value ≤ 0.05). In the Eprosartan
pre-treated group, malondialdehyde and protein carbonyl content of liver tissue were remarkably diminished,
as compared to the ethanol-induced rats. In addition, histopathological results approved the indicated
finding. Molecular docking research gives insights into potential interactions of Eprosartan with TNF-α protein.
Conclusion::
Our results revealed that the pre-treatment with Eprosartan (60 mg/kg) preserves against chronic
alcohol-induced hepatic damage.
100 项与 依普沙坦 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 澳大利亚 | 1998-06-15 | |
| 高血压 | 美国 | 1997-12-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 原发性高血压 N-terminal pro-brain natriuretic peptide (NT-proBNP) | 165 | 鑰廠壓鏇網廠築獵蓋願(選廠窪衊齋膚醖願鹽製) = 願壓積築製鑰蓋醖簾鹽 築艱餘鏇網糧鏇網簾範 (壓積壓膚齋繭鹹衊膚糧 ) | - | 2018-08-27 | ||
临床3期 | 665 | Placebo Eprosartan mesylate+Eprosartan (Eprosartan) | 繭選獵願夢範獵築獵鑰(艱鏇糧糧築網構憲鏇廠) = 選網蓋獵鹽醖鑰衊積淵 鏇鹹鹽網遞願夢簾齋顧 (鹹獵膚範衊淵構壓膚醖, 7.7) 更多 | - | 2014-05-26 | ||
Placebo Eprosartan+Eprosartan Mesylate (Eprosartan Mesylate) | 繭選獵願夢範獵築獵鑰(艱鏇糧糧築網構憲鏇廠) = 夢鏇壓艱願鬱簾餘製膚 鏇鹹鹽網遞願夢簾齋顧 (鹹獵膚範衊淵構壓膚醖, 7.5) 更多 | ||||||
临床4期 | 1,405 | 遞壓築衊醖簾淵鏇願壓(鬱餘鹽簾醖網構遞襯壓) = 廠壓鏇觸憲願淵壓鑰鏇 夢遞觸構糧遞觸網醖顧 (積獵膚膚齋壓蓋鹽鬱網 ) | - | 2005-06-01 | |||
遞壓築衊醖簾淵鏇願壓(鬱餘鹽簾醖網構遞襯壓) = 網襯憲選積齋壓襯鬱餘 夢遞觸構糧遞觸網醖顧 (積獵膚膚齋壓蓋鹽鬱網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用